✦Canada Post Xpress1–2 day delivery across CanadaFree on orders over $200
Your cart is empty
Oral GLP-1 Receptor Agonist
Orforglipron is a synthetic, non-peptide small molecule studied in research as an orally available agonist of the glucagon-like peptide-1 (GLP-1) receptor.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Orforglipron is a synthetic, non-peptide small molecule studied in research as an orally available agonist of the glucagon-like peptide-1 (GLP-1) receptor.
Laboratory and clinical investigations have examined its receptor-binding behavior and downstream metabolic signaling within controlled experimental frameworks.
Third-party tested for purity, ID, quantity.
Orforglipron (LY3502970) is a non-peptide GLP-1 receptor agonist characterized for oral bioavailability — a property that distinguishes it from peptide-based incretin analogues that require injection. Research has focused on its selective activation of the GLP-1 receptor and the resulting effects on metabolic signaling pathways.
In controlled studies it has been evaluated for receptor pharmacology, glycemic regulation, and body-weight endpoints under structured experimental conditions.
Orforglipron emerged from medicinal-chemistry programs seeking small-molecule alternatives to peptide GLP-1 receptor agonists. Its non-peptide scaffold was designed to retain receptor agonism while enabling oral dosing.
Subsequent phase 1–3 clinical research has characterized its pharmacological profile in type 2 diabetes and obesity research populations.
Investigations into orforglipron focus on GLP-1 receptor activation models and incretin-pathway metabolic regulation. Research frameworks evaluate receptor-binding selectivity, glycemic endpoints, and body-weight outcomes under controlled clinical and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of orforglipron. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
PubMedOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
PubMedThe pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
PubMedRelated
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$70.00
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$50.00
Immune-modulating peptide studied for T-cell signaling and immune system regulatory pathway research
From$60.00
GHRH analog studied for growth hormone regulation and metabolic pathway signaling research
From$90.00
